Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026)
Vivos Therapeutics (VVOS) reported Depreciation & Amortization (CF) of $454000.0 for Q1 2026, up 156.5% year-over-year from $177000.0 in Q1 2025, and up 2.71% quarter-over-quarter from $442000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $454000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $454000.0, up 156.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 159.15% YoY), and the FY2025 annual result was $1.3 million, up 125.3% from the prior year.
- Depreciation & Amortization (CF) rose to $454000.0 in Q1 2026 per VVOS's latest filing, from $442000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $454000.0 in Q1 2026 and troughed at $41000.0 in Q1 2022.
- A 5-year average of $213764.7 and a median of $169000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 76.84% in 2022, then surged 326.83% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $169000.0 in 2022, then retreated by 11.83% to $149000.0 in 2023, then dropped by 3.36% to $144000.0 in 2024, then surged by 206.94% to $442000.0 in 2025, then increased by 2.71% to $454000.0 in 2026.
- Business Quant data shows VVOS's Depreciation & Amortization (CF) at $454000.0 in Q1 2026, $442000.0 in Q4 2025, and $384000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 749.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 67.10 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 123.40 Mn |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | 454,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454,000.00 |
| Mar 31, 2026 | 454,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Dec 31, 2023 | 149,000.00 |